1Q EARNINGS: Gilead's $2.3bn in Sovaldi sales double consensus
This article was originally published in Scrip
Executive Summary
Sovaldi (sofosbuvir) didn't just beat market consensus estimates for about $1bn in first quarter 2014 sales, the January to March total for the Gilead Sciences hepatitis C drug more than doubled analyst predictions with $2.3bn in worldwide sales.